Johnson & Johnson (JNJ) beat Wall Street expectations in its first-quarter earnings report and raised its 2025 sales forecast by $700 ...

The company said China tariffs are hitting its products hardest and existing contracts limit its ability to raise prices.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

The most substantial impact comes from tariffs against China and retaliatory tariffs from China. Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall Street ...